Evidence map›Paper›PMID 28613199›Full record

ArticleMolecular imaging and radionuclide therapy2017

Efficacy of

Ali Ozan Öner, Evrim Sürer Budak, Funda Aydın, Ozan Salim, Orhan Kemal Yücel, Bahar Akkaya, Tayfur Toptaş, Adil Boz, Akın Yıldız, Fırat Güngör and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. EJNMMI reports · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ali Ozan ÖnerAfyon Kocatepe University Faculty of Medicine, Department of Nuclear Medicine, Afyonkarahisar, Turkey.
Evrim Sürer BudakAntalya Training and Research Hospital, Clinic of Nuclear Medicine, Antalya, Turkey.
Funda AydınAkdeniz University Faculty of Medicine, Department of Nuclear Medicine, Antalya, Turkey.
Ozan SalimAkdeniz University Faculty of Medicine, Department of Hematology, Antalya, Turkey.
Orhan Kemal YücelAkdeniz University Faculty of Medicine, Department of Hematology, Antalya, Turkey.
Bahar AkkayaAkdeniz University Faculty of Medicine, Department of Pathology, Antalya, Turkey.
Tayfur ToptaşMarmara University Faculty of Medicine, Department of Hematology, İstanbul, Turkey.
Adil BozAkdeniz University Faculty of Medicine, Department of Nuclear Medicine, Antalya, Turkey.
Akın YıldızAkdeniz University Faculty of Medicine, Department of Nuclear Medicine, Antalya, Turkey.
Fırat GüngörAkdeniz University Faculty of Medicine, Department of Nuclear Medicine, Antalya, Turkey.
Levent UndarAkdeniz University Faculty of Medicine, Department of Hematology, Antalya, Turkey.
Akdeniz University · TRAfyon Kocatepe University · TRAntalya Eğitim ve Araştırma Hastanesi · TRMarmara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCurrently

methodsThe study included 172 lymphoma cases who were admitted to Akdeniz University Medical School Department of Nuclear Medicine for initial staging with PET/CT. Visual and semiquantitative assessments were performed for PET/CT scan findings of the cases. The maximum standard uptake (SUV

resultsOn visual assessment of all the cases, PET/CT was found to yield 31% sensitivity and 85% specificity rate for detection of BMI. On visual assessment of HL cases, sensitivity rate was determined as 80%, and specificity as 78%, while in NHL cases the corresponding values were 24% and 90%, respectively. On semiquantitative assessment of HL cases, considering SUV

conclusionIn this study, a moderately high concordance was observed between PET/CT and BMB findings. PET/CT appears to be a significant method for detecting BMI. Although PET/CT is not a substitute for BMB, we suggest it can be used as a guide to biopsy site and a complementary imaging technique for BMB.

Indexed as

Hodgkin's lymphomanon-Hodgkin's lymphomapositron emission tomography/computerized tomography bone marrow biopsy.

Identifiers

PMID28613199
PMCPMC5472089
OpenAlexW2623181623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.